Head to head
The Scotts Miracle vs Nutrien
Side-by-side on the measures that matter, with a plain-English read. Full detail: SMG · NTR
SMG
The Scotts Miracle
49.40-2.22%
1-year price shape — -11% over the period
Quant Rating D · 27/100
vs
NTR
Nutrien
69.97-1.73%
1-year price shape — +19% over the period
Quant Rating C · 61/100
1-year performance, rebased to 100
Nutrien edges it on the scoreable measures. Nutrien has the highest Quant Rating (61); Nutrien has done best over the past year (+19%); Nutrien trades cheapest on trailing earnings.
| SMG | NTR | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 49.40 | 69.97 |
| Change today | -2.22% | -1.73% |
| 1-year return | -10.7% | +19.2% |
| Market cap | $2.88B | $33.39B |
| 52-week range | 47.90 – 74.53 | 50.05 – 81.99 |
| Valuation | ||
| P/E (TTM) | 40.49 | 14.16 |
| P/E percentile, own 5-yr range | 83rd | 41st |
| P/B | -13.78 | 1.29 |
| Dividend yield | 5.34% | 3.13% |
| Profitability & growth | ||
| EPS (TTM) | 2.47 | 4.66 |
| Net profit (TTM) | $143.80M | $2.22B |
| Revenue (TTM) | $3.48B | $28.21B |
| Revenue growth (YoY) | +1.1% | +3.6% |
| Gross margin | 31.7% | 31.0% |
| Operating margin | 13.5% | 14.7% |
| Net margin | 2.1% | 8.4% |
| Free cash flow (TTM) | $263.30M | $2.09B |
| Ownership & sentiment | ||
| Institutional ownership | 109.8% | 73.0% |
| Insider activity (12mo) | 45 buy / 5 sell | 1 buy / 2 sell |
| Short interest (% of float) | 8.1% | 1.6% |
| Analyst consensus | 60% buy / 40% hold (5) | 69% buy / 23% hold / 8% sell (13) |
| Analyst price target | $71 (+43%) | $78 (+11%) |
| StockVane view | ||
| StockVane Quant Rating | D (27) | C (61) |
| Company | ||
| Employees | 5,200 | 25,100 |
| Founded | 1868 | 2017 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.